JP2017515836A5 - - Google Patents

Download PDF

Info

Publication number
JP2017515836A5
JP2017515836A5 JP2016567364A JP2016567364A JP2017515836A5 JP 2017515836 A5 JP2017515836 A5 JP 2017515836A5 JP 2016567364 A JP2016567364 A JP 2016567364A JP 2016567364 A JP2016567364 A JP 2016567364A JP 2017515836 A5 JP2017515836 A5 JP 2017515836A5
Authority
JP
Japan
Prior art keywords
amino
methyl
phenyl
pyrazolo
fluoro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016567364A
Other languages
English (en)
Japanese (ja)
Other versions
JP6663857B2 (ja
JP2017515836A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2015/053174 external-priority patent/WO2015173683A1/en
Publication of JP2017515836A publication Critical patent/JP2017515836A/ja
Publication of JP2017515836A5 publication Critical patent/JP2017515836A5/ja
Application granted granted Critical
Publication of JP6663857B2 publication Critical patent/JP6663857B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016567364A 2014-05-14 2015-04-30 ピラゾロピリジンおよびピラゾロピリミジン Expired - Fee Related JP6663857B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461993138P 2014-05-14 2014-05-14
US61/993,138 2014-05-14
PCT/IB2015/053174 WO2015173683A1 (en) 2014-05-14 2015-04-30 Pyrazolopyridines and pyrazolopyrimidines

Publications (3)

Publication Number Publication Date
JP2017515836A JP2017515836A (ja) 2017-06-15
JP2017515836A5 true JP2017515836A5 (cg-RX-API-DMAC7.html) 2018-05-31
JP6663857B2 JP6663857B2 (ja) 2020-03-13

Family

ID=53264695

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016567364A Expired - Fee Related JP6663857B2 (ja) 2014-05-14 2015-04-30 ピラゾロピリジンおよびピラゾロピリミジン

Country Status (29)

Country Link
US (2) US9518052B2 (cg-RX-API-DMAC7.html)
EP (1) EP3143021B1 (cg-RX-API-DMAC7.html)
JP (1) JP6663857B2 (cg-RX-API-DMAC7.html)
KR (1) KR20170002623A (cg-RX-API-DMAC7.html)
CN (1) CN106459048A (cg-RX-API-DMAC7.html)
AP (1) AP2016009562A0 (cg-RX-API-DMAC7.html)
AR (1) AR100438A1 (cg-RX-API-DMAC7.html)
AU (1) AU2015260905A1 (cg-RX-API-DMAC7.html)
CA (1) CA2948587C (cg-RX-API-DMAC7.html)
CL (1) CL2016002888A1 (cg-RX-API-DMAC7.html)
CR (1) CR20160525A (cg-RX-API-DMAC7.html)
CU (1) CU20160167A7 (cg-RX-API-DMAC7.html)
DO (1) DOP2016000298A (cg-RX-API-DMAC7.html)
EA (1) EA201650029A1 (cg-RX-API-DMAC7.html)
EC (1) ECSP16087271A (cg-RX-API-DMAC7.html)
ES (1) ES2737696T3 (cg-RX-API-DMAC7.html)
GE (1) GEP20186921B (cg-RX-API-DMAC7.html)
IL (1) IL248970A0 (cg-RX-API-DMAC7.html)
MD (1) MD20160121A2 (cg-RX-API-DMAC7.html)
MX (1) MX2016014878A (cg-RX-API-DMAC7.html)
NI (1) NI201600170A (cg-RX-API-DMAC7.html)
PE (1) PE20161475A1 (cg-RX-API-DMAC7.html)
PH (1) PH12016502228A1 (cg-RX-API-DMAC7.html)
SG (1) SG11201609139WA (cg-RX-API-DMAC7.html)
SV (1) SV2016005318A (cg-RX-API-DMAC7.html)
TN (1) TN2016000503A1 (cg-RX-API-DMAC7.html)
TW (1) TWI591067B (cg-RX-API-DMAC7.html)
UY (1) UY36121A (cg-RX-API-DMAC7.html)
WO (1) WO2015173683A1 (cg-RX-API-DMAC7.html)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6663857B2 (ja) 2014-05-14 2020-03-13 ファイザー・インク ピラゾロピリジンおよびピラゾロピリミジン
US9403810B2 (en) 2014-05-14 2016-08-02 Novartis Ag Carboxamide derivatives
PL3371185T3 (pl) 2015-11-03 2021-04-06 Topivert Pharma Limited Pochodne 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pirydyny i 1,4,5,6,7,8-heksahydroimidazo[4,5-d]azepiny jako inhibitory kinaz janusowych
EP3865481A1 (en) 2015-11-03 2021-08-18 Topivert Pharma Limited 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as janus kinase inhibitors
HK1252685A1 (zh) 2015-11-03 2019-05-31 Theravance Biopharma R&D Ip, Llc 用於治疗呼吸疾病的jak激酶抑制剂化合物
EP3592743A1 (en) 2017-03-09 2020-01-15 Theravance Biopharma R&D IP, LLC Fused imidazo-piperidine jak inhibitors
AR111495A1 (es) 2017-05-01 2019-07-17 Theravance Biopharma R&D Ip Llc Compuestos de imidazo-piperidina fusionada como inhibidores de jak
CN110603255B (zh) 2017-05-01 2023-02-10 施万生物制药研发Ip有限责任公司 Jak抑制剂化合物的结晶型式
US10406148B2 (en) 2017-05-01 2019-09-10 Theravance Biopharma R&D Ip, Llc Methods of treatment using a JAK inhibitor compound
KR20200036004A (ko) * 2017-08-01 2020-04-06 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 Jak 키나아제 억제제로서 피라졸로 및 트리아졸로 비시클릭 화합물
CN119119039A (zh) 2017-11-03 2024-12-13 阿克拉瑞斯治疗股份有限公司 被取代的吡咯并吡啶jak抑制剂及其制造方法和使用方法
MX2021001558A (es) 2018-08-10 2021-04-28 Aclaris Therapeutics Inc Inhibidores de itk de pirrolopirimidina.
CN110833555B (zh) * 2018-08-15 2023-03-24 广西梧州制药(集团)股份有限公司 吡唑并嘧啶衍生物在治疗溃疡性结肠炎的用途
IL281152B2 (en) 2018-09-04 2023-12-01 Theravance Biopharma R& D Ip Llc Process for preparing jak inhibitors and intermediates thereof
FI3837258T3 (fi) 2018-09-04 2024-05-27 Theravance Biopharma R&D Ip Llc Dimetyyliaminoatsetidiiniamideja jak-estäjinä
WO2020051139A1 (en) 2018-09-04 2020-03-12 Theravance Biopharma R&D Ip, Llc 5 to 7 membered heterocyclic amides as jak inhibitors
EP3853229A1 (en) 2018-10-29 2021-07-28 Theravance Biopharma R&D IP, LLC 2-azabicyclo hexane compound as jak inhibitor
JP2022518741A (ja) 2019-01-23 2022-03-16 セラヴァンス バイオファーマ アール&ディー アイピー, エルエルシー JAKキナーゼ阻害剤としてのイミダゾ[1,5-a]ピリジン、1,2,4-トリアゾロ[4,3-a]ピリジンおよびイミダゾ[1,5-a]ピラジン
CN114075200A (zh) * 2020-08-14 2022-02-22 河南迈英诺医药科技有限公司 用于治疗重症肺炎的jak抑制剂化合物
PT3932919T (pt) * 2019-02-25 2024-07-30 Henan Medinno Pharmaceutical Tech Co Ltd Composto inibidor de jak e sua utilização
CN114075199A (zh) * 2020-08-14 2022-02-22 河南迈英诺医药科技有限公司 Jak抑制剂化合物及其用途
KR20220004726A (ko) 2019-05-02 2022-01-11 어클라리스 쎄라퓨틱스, 인코포레이티드 Jak 억제제로서의 치환된 피롤로피리딘
US20220235043A1 (en) * 2019-07-31 2022-07-28 Aclaris Therapeutics, Inc. Substituted sulfonamide pyrrolopyridines as jak inhibitors
EP4071145B1 (en) * 2019-12-30 2025-01-08 Liang Lu Jak inhibitor compound and use thereof
CN113101975B (zh) * 2020-01-13 2022-04-22 万华化学集团股份有限公司 一种多膦配体催化剂体系及其在乙烯齐聚反应的应用
EP4090426B1 (en) 2020-01-13 2025-12-31 Verge Analytics, Inc. Substitutes for pyrazolos and pyrimidines and their uses
TW202144343A (zh) 2020-03-02 2021-12-01 美商施萬生物製藥研發 Ip有限責任公司 Jak抑制劑化合物之結晶水合物
CN111548269B (zh) * 2020-04-29 2023-10-27 兰州大学 一种二芳基甲烷结构化合物的制备方法
GB202010408D0 (en) * 2020-07-07 2020-08-19 Reviral Ltd Pharmaceutical compounds
CA3192236A1 (en) 2020-09-10 2022-03-17 Tony Lahoutte Antibody fragment against fap
EP4359402A1 (en) 2021-06-25 2024-05-01 Theravance Biopharma R&D IP, LLC Imidazolo indazole compounds as jak inhibitors
CN115557947B (zh) * 2021-07-02 2024-04-02 成都百裕制药股份有限公司 吡唑并[4,3-c]吡啶衍生物及其在医药上的应用
CN113480543B (zh) * 2021-07-07 2022-05-17 无锡市第二人民医院 2,6,8-多取代咪唑并[1,2-a]吡嗪及其合成方法和应用
WO2023203135A1 (en) 2022-04-22 2023-10-26 Precirix N.V. Improved radiolabelled antibody
JP2025517625A (ja) 2022-05-02 2025-06-10 プレシリックス・ナームローゼ・ベンノートシヤープ プレターゲティング
WO2025217560A1 (en) * 2024-04-12 2025-10-16 Theravance Biopharma R&D Ip, Llc Triazolo indazole compounds as jak inhibitors

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
WO2000035298A1 (en) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Chewing gum containing medicament active agents
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
US20030139427A1 (en) * 2002-08-23 2003-07-24 Osi Pharmaceuticals Inc. Bicyclic pyrimidinyl derivatives and methods of use thereof
AU2003280838A1 (en) 2002-11-19 2004-06-15 Takeda Pharmaceutical Company Limited Indole derivatives as somatostatin agonists or antagonists
US20080234262A1 (en) * 2007-03-21 2008-09-25 Wyeth Pyrazolopyrimidine analogs and their use as mtor kinase and pi3 kinase inhibitors
JP4782239B2 (ja) 2007-04-18 2011-09-28 ファイザー・プロダクツ・インク 異常細胞増殖治療のためのスルホニルアミド誘導体
AU2008312631A1 (en) * 2007-10-16 2009-04-23 Wyeth Llc Thienopyrimidine and pyrazolopyrimidine compounds and their use as mTOR kinase and PI3 kinase inhibitors
CA2705303A1 (en) * 2007-11-07 2009-05-14 Foldrx Pharmaceuticals, Inc. Modulation of protein trafficking
WO2009070524A1 (en) * 2007-11-27 2009-06-04 Wyeth Pyrrolo[3,2-d]pyrimidine compounds and their use as pi3 kinase and mtor kinase inhibitors
AU2009205501A1 (en) * 2008-01-15 2009-07-23 Wyeth Llc 3H-[1,2,3]triazolo[4,5-d]pyrimidine compounds, their use as mTOR kinase and PI3 kinase inhibitors, and their syntheses
WO2009097446A1 (en) * 2008-01-30 2009-08-06 Genentech, Inc. Pyrazolopyrimidine pi3k inhibitor compounds and methods of use
US8163743B2 (en) * 2008-06-05 2012-04-24 GlaxoGroupLimited 4-carboxamide indazole derivatives useful as inhibitors of PI3-kinases
WO2009153261A1 (en) * 2008-06-18 2009-12-23 Solvay Pharmaceuticals Gmbh HYDROXYPHENYL-SUBSTITUTED PYRROLO[2,3d]PYRIMIDINE DERIVATIVES, PROCESSES AND INTERMEDIATE PRODUCTS FOR THEIR PREPARATION AND MEDICAMENTS CONTAINING THESE COMPOUNDS
EP2361902A4 (en) 2008-11-21 2012-04-25 Astellas Pharma Inc 4,6-DIAMINONICOTINSÄUREAMIDVERBINDUNG
AU2010224693B2 (en) * 2009-03-19 2016-07-28 Lifearc Compounds
WO2012045195A1 (en) 2010-10-09 2012-04-12 Abbott Laboratories Pyrrolopyrimidines as fak and alk inhibiters for treatment of cancers and other diseases
US8575336B2 (en) * 2011-07-27 2013-11-05 Pfizer Limited Indazoles
JP6663857B2 (ja) 2014-05-14 2020-03-13 ファイザー・インク ピラゾロピリジンおよびピラゾロピリミジン

Similar Documents

Publication Publication Date Title
JP2017515836A5 (cg-RX-API-DMAC7.html)
JP2013523710A5 (cg-RX-API-DMAC7.html)
ES2642586T3 (es) Compuestos heterocíclicos condensados como moduladores de canales iónicos
RU2018138050A (ru) Производные тиазолопиридина как агонисты gpr119
TWI756482B (zh) 治療活性化合物及其使用方法
RU2018123825A (ru) Соединения и способы для модуляции киназ, и показания для этого
JP2006519205A (ja) ピラゾロピリジン誘導体
JP2018534326A5 (cg-RX-API-DMAC7.html)
HRP20171913T1 (hr) Aminopirimidinilni spojevi kao inhibitori jak
CN105209460A (zh) 作为突变idh抑制剂的3-嘧啶-4-基-噁唑烷-2-酮化合物
JP2019504009A5 (cg-RX-API-DMAC7.html)
RU2018138047A (ru) Гетероциклические вещества - агонисты gpr119
KR20030030030A (ko) IKB-키나제 (IKK-β) 억제 활성을 갖는 피리딘 유도체
TWI455715B (zh) 4-(4-氰基-2-硫基芳基)二氫嘧啶酮類及其用途
HRP20212000T1 (hr) Aminotriazolopiridini kao inhibitori kinaze
JP2015514794A5 (cg-RX-API-DMAC7.html)
JP2019519484A5 (cg-RX-API-DMAC7.html)
JP2017500362A5 (cg-RX-API-DMAC7.html)
JP2013544840A5 (cg-RX-API-DMAC7.html)
JP2013502429A5 (cg-RX-API-DMAC7.html)
AU2011272800A1 (en) sGC stimulators
JP2012532931A5 (cg-RX-API-DMAC7.html)
JP2014527511A5 (cg-RX-API-DMAC7.html)
JP2011518219A5 (cg-RX-API-DMAC7.html)
JP2019529443A5 (cg-RX-API-DMAC7.html)